Celyad Oncology (LTS:0QFK) Operating Cash Flow per Share : €0.00 (TTM As of Jun. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Celyad Oncology Operating Cash Flow per Share?

Celyad Oncology's operating cash flow per share for the three months ended in Jun. 2023 was €0.00. Celyad Oncology's operating cash flow per share for the trailing twelve months (TTM) ended in Jun. 2023 was €0.00.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 18.00% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 19.90% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 3.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Celyad Oncology's Operating Cash Flow per Share or its related term are showing as below:

LTS:0QFK' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -34.7 Med: 7 Max: 24.5
Current: 18

During the past 12 years, Celyad Oncology's highest 3-Year average Operating Cash Flow per Share Growth Rate was 24.50% per year. The lowest was -34.70% per year. And the median was 7.00% per year.

LTS:0QFK's 3-Year OCF Growth Rate is ranked better than
65.91% of 1235 companies
in the Biotechnology industry
Industry Median: 3.3 vs LTS:0QFK: 18.00

Celyad Oncology Operating Cash Flow per Share Historical Data

The historical data trend for Celyad Oncology's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celyad Oncology Operating Cash Flow per Share Chart

Celyad Oncology Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Operating Cash Flow per Share

Get a 7-Day Free Trial

-2.45

-2.25

-1.98

-1.71

-1.24

Celyad Oncology Quarterly Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Dec22	Jun23
Operating Cash Flow per Share	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Celyad Oncology's Operating Cash Flow per Share

For the Biotechnology subindustry, Celyad Oncology's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Celyad Oncology's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celyad Oncology's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Celyad Oncology's Price-to-Operating-Cash-Flow falls into.

Celyad Oncology Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Celyad Oncology's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2022 is calculated as

Operating Cash Flow per Share (A: Dec. 2022 )	=	Cash Flow from Operations (A: Dec. 2022 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2022 )
	=	-28.01	/	22.594
	=	-1.24

Celyad Oncology's Operating Cash Flow per Share for the quarter that ended in Dec. 2022 is calculated as

Operating Cash Flow per Share (Q: Jun. 2023 )	=	Cash Flow from Operations (Q: Jun. 2023 )	/	Shares Outstanding (Diluted Average) (Q: Jun. 2023 )
	=	0	/	22.600
	=	0.00

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00

Celyad Oncology Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Celyad Oncology's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Celyad Oncology (LTS:0QFK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celyad Oncology SA (LTS:0QFK) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

CYAD:Belgium

Address

Rue Edouard Belin 2, Axis Business Park, Brabant Wallon, Mont-Saint-Guibert, BEL, 1435

Website

https://www.celyad.com

Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of innovative technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments.

Celyad Oncology (LTS:0QFK) Headlines

No Headlines